COUNTERPOINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? No.

[1]  A. Anzueto,et al.  Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators. , 2018, Chest.

[2]  Y. Hsu,et al.  Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study , 2018, JAMA internal medicine.

[3]  P. Kardos,et al.  The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study – the FAVOR study , 2017, International journal of chronic obstructive pulmonary disease.

[4]  M. Miravitlles,et al.  Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis , 2017, Respiratory Research.

[5]  Y. Li,et al.  Tiotropium in Early‐Stage Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[6]  D. Halpin,et al.  When is dual bronchodilation indicated in COPD? , 2017, International journal of chronic obstructive pulmonary disease.

[7]  M. Cazzola,et al.  Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. , 2017, Respiratory medicine.

[8]  Pere Almagro,et al.  Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable , 2017 .

[9]  S. Suissa,et al.  Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events , 2017, European Respiratory Journal.

[10]  A. Valipour,et al.  GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort , 2017, European Respiratory Journal.

[11]  R. Casaburi,et al.  Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD , 2017, European Respiratory Journal.

[12]  Bartolomé R. Celli,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. , 2017, Archivos de bronconeumologia.

[13]  M. Cazzola,et al.  LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment , 2017, European Respiratory Review.

[14]  M. Cazzola,et al.  A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.

[15]  Carl Llor,et al.  Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. , 2016, Respiratory medicine.

[16]  H. Watz,et al.  Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) , 2015, European Respiratory Journal.

[17]  M. Miravitlles,et al.  The asthma–chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges , 2015, Current opinion in pulmonary medicine.

[18]  D. Jadayel,et al.  Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. , 2014, Respiratory medicine.

[19]  T. To,et al.  Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. , 2013, JAMA internal medicine.

[20]  E. Bateman,et al.  Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study , 2013, European Respiratory Journal.